As many laboratories face demands to turn around faster, more accurate patient test results against a backdrop of increasingly stringent quality control and tighter budgets, the search is on for tools to help meet ever-stretching targets.
Researchers at Johns Hopkins Bayview Medical Center used two relatively simple tactics to significantly reduce the number of unnecessary blood tests to assess symptoms of heart attack and chest pain and to achieve a large decrease in patient charges.
Laboratories are an essential part of effective modern healthcare. They provide clinicians with vital information that helps them make life-saving decisions, diagnose conditions and monitor patient treatment.
For several decades pathologists worldwide have been under increasing pressure to handle a steady increase in laboratory tests with a steady decrease in finance and staff.
The GenSPEED Test System developed by Greiner Bio-One combines crude lysis of bacteria with multiplex-PCR before the final automated analysis of PCR-products in the new GenSPEED R2 device.
For several decades, pathologists worldwide have been under increasing pressure to handle a steady increase in laboratory tests with a steady decrease in the amount of financial and staff resources. Add to this the escalating volume of increasingly complex, sophisticated testing and the importance of pathology informatics is evident.
Scientists in the UK are working to develop a hand-held testing device to provide same day diagnosis from a patient’s bedside. The device will use disposable cartridges and utilise printed circuit board technology (PCB) that will allow a fast and low-cost diagnosis.
Some years ago telepathology – a complex but well developed procedure where histology specimens are photographed using a camera mounted on a microscope and transmitted – was thought to be the wave of the future.
Having convinced medical labs across Denmark that its suite of image analysis software can provide a solution to the crushing burden of in vitro diagnostics (IVD), VisioPharm is offering it to pathologists worldwide
This April, in San Jose, California, the portable lab took central stage at the American Association for Clinical Chemistry’s (AACC) annual forum for emerging clinical diagnostic technologies – a most appropriate topic for the Silicon Valley venue where so many world-changing computer and communications innovations have been born.
Postoperative infections after knee or hip joint replacements are among the most feared complications in orthopaedic surgery. At the EFORT Congress in London current research was presented that provides new insights in this field: Fracture patients are especially vulnerable to infection. New biomarkers should improve early diagnosis of risky infections.
Future of DNA sequencing will shift from a laboratory-based setup to point of care testing in the next 5 years
Reliable results can only be achieved in urine diagnostics, if correct preanalytical conditions are ensured. Urine collection, specimen transport and further storage are critical influential factors for sample quality and can affect the results.
About four years ago, Samsung Electronics Co. – specialist in electronic components and mobile phone sets, was recognised by its revenues as the world’s largest IT company, displacing Apple Inc.
A small prick to sample blood instead of complex pathological or other diagnostic procedures – this is how early cancer diagnosis will be in the near future. Blood tests to diagnose tumorous diseases early are already being researched for clinical use.
Despite a slight drop in sales in 2013 compared to the previous year, for 2014 the German medical diagnostics manufacturers anticipate a positive business development, according to the trend indicator presented by the business association Verband der Diagnostika-Industrie (VDGH) in Berlin.
Olympus launches its OlyVIA Mobile iPad App, an image viewer dedicated to virtual slides.
Offering attractive procurement strategies will boost adoption of high-end tools
GE and Thermo Fisher Scientific announced yesterday that they have entered into an agreement for GE Healthcare to acquire Thermo Fisher’s HyClone cell culture media and sera, and gene modulation and magnetic beads businesses for approximately $1.06 billion.
Down’s syndrome (also referred to as trisomy 21) is a genetic disorder caused by the presence of all or part of an extra copy of chromosome 21 in a person’s DNA. Current screening for Down’s syndrome and other trisomy conditions includes a combined test done between the 11th and 13th weeks of pregnancy.
The number of patients treated with implants – from cardiac pacemakers, heart valves and vascular implants to artificial hips and knees – is rising worldwide.
Over the past decade the use of point-of-care testing (POCT) in European and North American hospitals has steadily increased, stimulated by the objectives of accelerating diagnostic treatment, increasing efficiency and improving patient outcomes.
Today, Siemens Healthcare Diagnostics Inc. announces that it has entered into a master collaboration agreement with Pfizer Inc. to design, develop and commercialize diagnostic tests for therapeutic products across Pfizer’s pipeline.
Ahead of regulatory approval that is expected before the end of the year, Trinity Biotech chose Medica to present the novel point-of-care (POC) analyzer Meritas with the Troponin I (TnI) that are expected to disrupt a €700 million market.
Born in the USA out of the anthrax scare that followed the 9/11 attacks, the formation of a network of laboratories kept on 24/7 alert against potential bio-terrorism was introduced in France at the end of 2001.